All dosing in the drisapersen clinical program had been placed on hold by GSK on September 20, 2013, upon announcement of the DEMAND III study results. The re-dosing
The Phase 3 clinical trial is designed to demonstrate the superiority, in terms of mortality at 28 days, of a plazomicin-based regimen compared with a colistin-based regimen in
The partnership establishes a major dystonia research prize to expand public awareness, acknowledge key scientific discoveries and incentivize the work of dedicated researchers in dystonia, an under-funded movement
The company will be developing an advanced, automated prototype system for human tissue immuno-oncology profiling, which it will deploy at two leading medical institutions over the course of
MGB-BP-3 is the first antibacterial for over a decade with a novel mode of action from a truly novel class to be developed globally. Funding of £2.7m has
The GNHA assembled this summer to discuss the current VMS landscape, concluding it is riddled with inconsistent messages and misconceptions that ultimately may confuse both healthcare professionals and
ChromaDex’s NIAGEN™ is the first and only commercially available form of nicotinamide riboside (NR), a naturally occurring no-flush vitamin B3 metabolite found in milk. Published research has shown
In this analysis, survival in patients with HPP at high risk of death who were treated with asfotase alfa for up to five years was significantly improved (89%
Based on the data contained in the NDA for Saxenda, the FDA asked the panel members to discuss whether Novo Nordisk has provided adequate evidence to establish the
The Committee’s recommendation will be considered by the FDA in its review of the company’s Biologics License Application (BLA) for Natpara, which has a Prescription Drug User Fee
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.